

imidazolyl optionally substituted on a nitrogen atom with C₃-C₆ cycloalkyl, morpholin-4-yl, pyrrolidin-1-yl, -CO₂H, -CO(C₁-C₄ alkoxy), -CO(NR⁸R⁹), -NR⁸R⁹ or -(morpholin-4-yl)carbonyl;

R⁶ is hydrogen, C₁-C₁₀ alkyl optionally substituted with up to three halo substituents, 1-amino-2-methoxyethyl-1-yl, C₃-C₆ cycloalkyl, pyridinyl optionally substituted with C₁-C₄ alkyl, trifluoromethyl, carboxyl, or (C₁-C₄ alkoxy)carbonyl, pyridinyl-N-oxide, pyrazinyl, pyrimidinyl, imidazolyl, morpholin-4-yl optionally substituted with up to two C₁-C₄ alkyl groups, [1,4]oxazepin-4-yl, azetidin-4-yl, tetrahydropyran-4-yl, 3-methyl-6,7-dihydropyrrolo[1,2-a]imidazol-6-yl, piperazin-4-yl optionally substituted in the 4 position with phenyl or C₁-C₄ alkyl, pyrrolidin-1-yl, piperidin-1-yl optionally substituted in the 4-position with oxo or geminal dimethyl, piperidin-4-yl optionally substituted in the 1-position with (C₁-C₄ alkoxy)carbonyl or C₁-C₄ alkyl, or -(C₁-C₄ alkylene)-R¹⁰;

R⁷ is C₁-C₆ alkyl optionally substituted with halo, 2-methoxyethyl-1-yl, -(C₁-C₂ alkylene)-(morpholin-4-yl or pyrrolidin-2-on-1-yl), or phenyl optionally substituted with one or two substituents independently selected from the group consisting of halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, and trifluoromethyl;

R⁸ is hydrogen or C₁-C₆ alkyl optionally substituted with C₁-C₄ alkoxy;

R⁹ is hydrogen or C₁-C₆ alkyl optionally substituted with C₁-C₄ alkoxy;

R¹⁰ is -OCH₂CH₂OCH₃, -NR¹⁴R¹⁵, C₃-C₆ cycloalkyl, morpholin-4-yl, thiomorpholin-4-yl, 1,1-dioxothiomorpholin-4-yl, piperidin-1-yl, pyrrolidin-2-yl optionally substituted at the 1-position with C₁-C₄ alkyl, or imidazolyl optionally substituted with nitro;

Ar is benzofur-4-yl, benzofur-7-yl, benzothien-4-yl, benzothien-7-yl, 1-(R¹¹)benzimidazol-4-yl, 1-(R¹¹)indol-4-yl, indol-7-yl, isoquinolin-5-yl, 2,3-dihydrobenzo-fur-4-yl, 2,3-dihydrobenzofur-7-yl, 1,3-dihydroisobenzofur-4-yl, 1,3-dihydroisobenzofur-5-yl, benzo[1,3]dioxol-4-yl, benzo[1,3]dioxol-5-yl, 2,3-dihydrobenzo[1,4]dioxin-5-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, 2',2'-difluorobenzo[1,3]dioxol-4-yl, or 2',2'-difluorobenzo[1,3]dioxol-5-yl each optionally substituted in the phenyl ring with substituents R¹² and R¹³, or Ar is a group selected from imidazo[1,2-a]pyridin-3-yl optionally substituted with one or two substituents independently selected from the group consisting of halo, amino, C₁-C₄ alkyl, C₁-C₄ alkoxy, benzyloxy, cyano, and trifluoromethyl, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl, imidazo[1,2-a]pyridin-5-yl, imidazo[1,2-a]pyrimidin-3-yl optionally substituted with amino, imidazo[1,2-c]pyrimidin-3-yl, imidazo[1,2-a]pyrazin-3-yl, imidazo[1,2-b]pyridazin-3-yl, imidazo[2,1-b]thiazol-3-yl, thiazolo[3,2-b][1,2,4]triazol-6-yl, furo[3,2-c]pyridin-7-yl optionally

substituted with halo or $\text{-NR}^{14}\text{R}^{15}$, thieno[3,2-*b*]pyridin-7-yl, pyrazolo[2,3-*a*]pyridin-3-yl, pyrazolo[1,5-*a*]pyridin-3-yl, or 4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl;

R^{11} is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or $\text{-(CH}_2\text{)}_p\text{-G}$;

R^{12} is halo, hydroxy, amino, $\text{C}_1\text{-C}_4$ alkoxy, $\text{-NHC(O)(C}_1\text{-C}_4\text{ alkyl)}$, or $\text{-O-(CH}_2\text{)}_p\text{-G}$;

R^{13} is halo;

p is 2, 3, 4, or 5;

G is hydroxy or $\text{NR}^{14}\text{R}^{15}$;

R^{14} and R^{15} are independently selected from the group consisting of hydrogen and $\text{C}_1\text{-C}_5$ alkyl;

R^{16} is hydrogen or cyano,

R^{17} is $\text{-NR}^8\text{R}^9$, $\text{C}_1\text{-C}_4$ alkyl, morpholin-4-yl, or piperidin-1-yl; or a pharmaceutically acceptable salt thereof, ~~provided that when *n* is 0, *W-X-Y* is not $\text{-CH(R}^{21}\text{)-N(R}^{22}\text{)-C(O)-}$.~~

Claim 2 (cancelled)

Claim 3 (original): A compound of Claim 1 where Ar is imidazo[1,2-*a*]pyridin-3-yl optionally substituted with one or two groups independently selected from halo, $\text{C}_1\text{-C}_4$ alkyl, or $\text{C}_1\text{-C}_4$ alkoxy.

Claim 4 (cancelled)

Claim 5 (currently amended): A compound of ~~Claim 4~~ Claim 3 where R^2 is -C(O)R^6 .

Claim 6 (previously presented): A pharmaceutical formulation comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

Claims 7 - 8 (cancelled)

Claim 9 (previously presented): A method of inhibiting GSK-3 in a mammal comprising administering to a mammal in need of such treatment a GSK-3 inhibiting amount of a compound of Claim 1.

Claim 10 (previously presented): A method of stimulating bone deposition in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 1.

Claim 11 (new): A compound of Claim 5 where R⁶ is piperidin-1-yl.

Claim 12 (new): A compound of Claim 11 where R¹ is fluoro.

Claim 13 (new): 3-(9-Fluoro-6-((piperidin-1-yl)carbonyl)-6,7-dihydro-6H-[1,4]diazepino-[6,7,1-hi]indol-1-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxopyrrole, or a pharmaceutically acceptable salt thereof.

Claim 14 (new): 3-(9-Fluoro-6-((piperidin-1-yl)carbonyl)-6,7-dihydro-6H-[1,4]diazepino-[6,7,1-hi]indol-1-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-2,5-dioxopyrrole hydrochloride.

Claim 15 (new): A pharmaceutical formulation comprising a compound of Claim 13 in combination with a pharmaceutically acceptable carrier, diluent or excipient.